Activity of esorubicin in recurrent malignant lymphoma: A southwest oncology group study

Thomas P Miller, Steve Dahlberg, Sydney E. Salmon, Steven K. Williamson, Robert J. Belt, Bruce W. Dana, Richard I. Fisher

Research output: Contribution to journalArticle

Abstract

A phase II trial of esorubicin (4′ deoxydoxorubicin) was conducted by the Southwest Oncology Group in 88 assessable patients with non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD) at the time of first relapse. Esorubicin was administered at two dose levels: 25 mg/m2 for patients at risk for excessive myelosuppression, and at 30 mg/m2 for all others at 21-day intervals. Overall, 33 of 88 patients (38%) responded to treatment including three complete remissions (CRs; 3%) and 30 partial remissions (PRs; 34%), with the median duration of response lasting 6.2 months. Response rates did not differ significantly by histologic subtype: 31% of 26 patients with favorable NHL, 33% of 43 patients with unfavorable NHL, and 58% of 19 patients with HD. Twelve of 33 responding patients (36%) had relatively durable remissions lasting from 1 to more than 4 years. Leukopenia (< 3,000 cells per microliter) was seen in 65 of 88 patients (74%) and was severe (< 1,000 cells per microliter) in 20 of 88 patients (23%). Clinical signs or symptoms of congestive heart failure were not seen and the ejection fraction (EF) fell 10% to 20% in three patients. Esorubicin is an active agent in patients with NHL or HD at the time of first relapse.

Original languageEnglish (US)
Pages (from-to)1204-1209
Number of pages6
JournalJournal of Clinical Oncology
Volume9
Issue number7
StatePublished - 1991
Externally publishedYes

Fingerprint

Lymphoma
Non-Hodgkin's Lymphoma
Hodgkin Disease
esorubicin
Recurrence
Leukopenia
Proxy
Signs and Symptoms
Heart Failure

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Miller, T. P., Dahlberg, S., Salmon, S. E., Williamson, S. K., Belt, R. J., Dana, B. W., & Fisher, R. I. (1991). Activity of esorubicin in recurrent malignant lymphoma: A southwest oncology group study. Journal of Clinical Oncology, 9(7), 1204-1209.

Activity of esorubicin in recurrent malignant lymphoma : A southwest oncology group study. / Miller, Thomas P; Dahlberg, Steve; Salmon, Sydney E.; Williamson, Steven K.; Belt, Robert J.; Dana, Bruce W.; Fisher, Richard I.

In: Journal of Clinical Oncology, Vol. 9, No. 7, 1991, p. 1204-1209.

Research output: Contribution to journalArticle

Miller, TP, Dahlberg, S, Salmon, SE, Williamson, SK, Belt, RJ, Dana, BW & Fisher, RI 1991, 'Activity of esorubicin in recurrent malignant lymphoma: A southwest oncology group study', Journal of Clinical Oncology, vol. 9, no. 7, pp. 1204-1209.
Miller TP, Dahlberg S, Salmon SE, Williamson SK, Belt RJ, Dana BW et al. Activity of esorubicin in recurrent malignant lymphoma: A southwest oncology group study. Journal of Clinical Oncology. 1991;9(7):1204-1209.
Miller, Thomas P ; Dahlberg, Steve ; Salmon, Sydney E. ; Williamson, Steven K. ; Belt, Robert J. ; Dana, Bruce W. ; Fisher, Richard I. / Activity of esorubicin in recurrent malignant lymphoma : A southwest oncology group study. In: Journal of Clinical Oncology. 1991 ; Vol. 9, No. 7. pp. 1204-1209.
@article{48df88f741ac4551abf43371412d0440,
title = "Activity of esorubicin in recurrent malignant lymphoma: A southwest oncology group study",
abstract = "A phase II trial of esorubicin (4′ deoxydoxorubicin) was conducted by the Southwest Oncology Group in 88 assessable patients with non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD) at the time of first relapse. Esorubicin was administered at two dose levels: 25 mg/m2 for patients at risk for excessive myelosuppression, and at 30 mg/m2 for all others at 21-day intervals. Overall, 33 of 88 patients (38{\%}) responded to treatment including three complete remissions (CRs; 3{\%}) and 30 partial remissions (PRs; 34{\%}), with the median duration of response lasting 6.2 months. Response rates did not differ significantly by histologic subtype: 31{\%} of 26 patients with favorable NHL, 33{\%} of 43 patients with unfavorable NHL, and 58{\%} of 19 patients with HD. Twelve of 33 responding patients (36{\%}) had relatively durable remissions lasting from 1 to more than 4 years. Leukopenia (< 3,000 cells per microliter) was seen in 65 of 88 patients (74{\%}) and was severe (< 1,000 cells per microliter) in 20 of 88 patients (23{\%}). Clinical signs or symptoms of congestive heart failure were not seen and the ejection fraction (EF) fell 10{\%} to 20{\%} in three patients. Esorubicin is an active agent in patients with NHL or HD at the time of first relapse.",
author = "Miller, {Thomas P} and Steve Dahlberg and Salmon, {Sydney E.} and Williamson, {Steven K.} and Belt, {Robert J.} and Dana, {Bruce W.} and Fisher, {Richard I.}",
year = "1991",
language = "English (US)",
volume = "9",
pages = "1204--1209",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "7",

}

TY - JOUR

T1 - Activity of esorubicin in recurrent malignant lymphoma

T2 - A southwest oncology group study

AU - Miller, Thomas P

AU - Dahlberg, Steve

AU - Salmon, Sydney E.

AU - Williamson, Steven K.

AU - Belt, Robert J.

AU - Dana, Bruce W.

AU - Fisher, Richard I.

PY - 1991

Y1 - 1991

N2 - A phase II trial of esorubicin (4′ deoxydoxorubicin) was conducted by the Southwest Oncology Group in 88 assessable patients with non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD) at the time of first relapse. Esorubicin was administered at two dose levels: 25 mg/m2 for patients at risk for excessive myelosuppression, and at 30 mg/m2 for all others at 21-day intervals. Overall, 33 of 88 patients (38%) responded to treatment including three complete remissions (CRs; 3%) and 30 partial remissions (PRs; 34%), with the median duration of response lasting 6.2 months. Response rates did not differ significantly by histologic subtype: 31% of 26 patients with favorable NHL, 33% of 43 patients with unfavorable NHL, and 58% of 19 patients with HD. Twelve of 33 responding patients (36%) had relatively durable remissions lasting from 1 to more than 4 years. Leukopenia (< 3,000 cells per microliter) was seen in 65 of 88 patients (74%) and was severe (< 1,000 cells per microliter) in 20 of 88 patients (23%). Clinical signs or symptoms of congestive heart failure were not seen and the ejection fraction (EF) fell 10% to 20% in three patients. Esorubicin is an active agent in patients with NHL or HD at the time of first relapse.

AB - A phase II trial of esorubicin (4′ deoxydoxorubicin) was conducted by the Southwest Oncology Group in 88 assessable patients with non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD) at the time of first relapse. Esorubicin was administered at two dose levels: 25 mg/m2 for patients at risk for excessive myelosuppression, and at 30 mg/m2 for all others at 21-day intervals. Overall, 33 of 88 patients (38%) responded to treatment including three complete remissions (CRs; 3%) and 30 partial remissions (PRs; 34%), with the median duration of response lasting 6.2 months. Response rates did not differ significantly by histologic subtype: 31% of 26 patients with favorable NHL, 33% of 43 patients with unfavorable NHL, and 58% of 19 patients with HD. Twelve of 33 responding patients (36%) had relatively durable remissions lasting from 1 to more than 4 years. Leukopenia (< 3,000 cells per microliter) was seen in 65 of 88 patients (74%) and was severe (< 1,000 cells per microliter) in 20 of 88 patients (23%). Clinical signs or symptoms of congestive heart failure were not seen and the ejection fraction (EF) fell 10% to 20% in three patients. Esorubicin is an active agent in patients with NHL or HD at the time of first relapse.

UR - http://www.scopus.com/inward/record.url?scp=0025763197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025763197&partnerID=8YFLogxK

M3 - Article

C2 - 2045860

AN - SCOPUS:0025763197

VL - 9

SP - 1204

EP - 1209

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 7

ER -